Pharma Effluent Chemistry and Treatability Study

SARTIME's pharma offering starts before equipment selection. API manufacturing uses batch processes, different molecules, solvents and reaction routes, so the effluent varies by product campaign and cannot be designed only from a combined COD number.

The study identifies raw materials, manufacturing steps, effluent sources, solvent and salt contribution, existing treatment limits and the right segregation route. This is where waste segregation, biodegradability checks, detoxification trials and feasibility studies are used to decide whether SBR, MBR, RO, evaporation or a combination will deliver reliable ZLD performance.

>20 pharma factories consultancy and water audit projects executed for pharma industries Multiple process routes studied sulphonation, Friedel-Crafts reaction, nitrification, extraction, purification and packaging streams reviewed High COD, TDS and solvent load pharma source chemistry mapped before treatment selection Recalcitrant chemicals handled Butanediol, Hexamine, Seracin, Pentaerythritol, Amines, DMF and DMSO included in difficult-effluent work

Detoxification system for complex chemical wastewater

Modified SBR for API COD and Ammonia Reduction

SARTIME's modified SBR offering is designed for API effluent where conventional activated sludge does not give the required reduction. The system is operated in batch mode so the entire feed receives the required reaction time, avoiding short-circuiting and uneven biological exposure.

The differentiation is biological process control, not only tank volume. SARTIME uses special inoculum, daily monitoring of bacterial health and analytical checks before fresh feed is added. This makes the SBR stage the load-reduction engine before RO and evaporation.

20,000 ppm to <1,000 ppm API COD reduced by SARTIME modified SBR technology <500 mg/L COD target achieved for difficult drug-intermediate load after process development <50 mg/L ammonia ammonia reduced after biological treatment development 9 days batch residence time used so all molecules remain in treatment for the same duration 3 years treatment process development work completed for difficult pharma effluent 70% to 95% RO recovery path enabled after biological COD reduction and second-stage RO

Pharma biological treatment process installation

MBR Technology for Pharma Wastewater

SARTIME's MBR offering is used where biological clarification must be strengthened before downstream RO. In the pharma API application, MBR improves the treated-water quality sent to membrane recovery and reduces the cleaning burden on the following RO stage.

The MBR section also supports recovery improvement from older Disc RO operation. With better biological separation ahead of RO, the plant can recover more water with less daily cleaning interruption.

4,000 mg/L to 1,500 mg/L COD reduced from gravity-settled water to post-MBR water 50% to 85% Disc RO recovery increased after MBR-supported treatment 4 hours daily cleaning removed RO cleaning frequency reduced from daily cleaning to weekly cleaning 2 hours once in 2 months in-situ cleaning requirement after improved MBR + RO operation API pharma implementation MBR successfully applied in an API pharma factory in Hyderabad

MBR process flow diagram for pharma wastewater

MBR treatment sample jars before and after treatment

High-Recovery RO for Pharma ZLD

SARTIME's high-recovery RO offering is built around the fact that pharma RO is not raw-water RO. The upstream biological treatment, waste segregation and membrane design must work together so maximum water is recovered before the evaporator.

The Pharma material highlights SARTIME's move from Disc RO dependence to successful Spiral wound RO application in pharmaceutical wastewater recovery. The objective is simple: recover more reusable water, produce better permeate, and reduce the reject volume that reaches thermal ZLD.

95% RO recovery recovery target reached with COD reduction and second-stage RO >85% water recovered effluent recovery achieved in pharma ZLD operation <10 ppm COD recovered permeate quality achieved >4 years membrane life membrane operating life achieved in difficult effluent service Spiral wound RO introduced pharmaceutical wastewater recovery moved beyond Disc RO where design permits Less RO reject evaporator feed reduced by recovering maximum water through RO

RO fouling concern for wastewater recovery

Recovered Water Reuse as Boiler Feed

SARTIME's reuse offering goes beyond sending recovered water only to cooling tower makeup. In pharma applications, the high-recovery RO system is positioned to produce permeate quality suitable for higher-grade reuse, including boiler feed where the project design and polishing requirements support it.

The reuse approach treats pharma effluent as a recoverable water source, not only a disposal problem. The stronger the biological and RO performance, the more useful the recovered water becomes inside the plant.

<10 ppm COD permeate quality achieved for recovered water Boiler feed reuse recycled water reused for boiler feed instead of only cooling tower use >85% recovery more recovered water available for internal reuse 95% recovery path second-stage RO used where required to increase recovery

Ammonia and Volatile COD Control

SARTIME's ammonia-control offering addresses a Pharma ZLD problem that RO alone cannot solve. Ammonium salts are rejected by RO membranes, and when the reject is sent to the evaporator, the condensate can return with higher ammonia. Without correcting this loop, the plant keeps carrying ammonia back into treatment.

SARTIME uses batch biological treatment, special inoculum, controlled feed addition and analytical monitoring to reduce both COD and ammonia before the recovery stages. This protects the RO and prevents the evaporator from becoming the place where unresolved chemistry is recycled.

15,000 mg/L COD feed evaporator condensate and low-TDS stream treated before recovery 400 mg/L ammonia feed ammonia-bearing stream handled through biological treatment design <500 mg/L COD difficult COD reduced before downstream RO and evaporation <50 mg/L ammonia ammonia reduced after SARTIME's biological treatment development Ammonia loop controlled RO reject and evaporator condensate problem addressed before it repeats

RO Fouling Control for Pharma Effluent

SARTIME's RO fouling control offering for pharma focuses on making Spiral wound membranes work in effluent service. Pharma wastewater can carry organics, salts, solvents and biological residues that raw-water RO designs are not built to handle.

The offering combines wastewater analysis, lab testing, pilot trials, stronger pretreatment, conservative flux, conservative recovery, higher pipe sizes, higher pump sizes and better diagnosis of membrane behavior. The purpose is to protect permeate flow, salt rejection and membrane life while keeping recovery high.

Up to 100 NTU treated effluent feed handled by SARTIME's effluent RO design approach 95% recovery design target troubleshooting and RO design focused on maximum recovery before evaporation >4 years membrane life membrane life achieved in difficult effluent recovery service Lab and pilot checks wastewater tested before ETP and RO design finalization Higher pipe and pump sizing effluent RO design strengthened beyond raw-water RO assumptions Pressure, flow and rejection watched membrane behavior diagnosed before fouling becomes plant failure

RO fouling visual for wastewater service

RO membrane for pharma wastewater recovery

Evaporator Load Reduction and MFTL Evaporator

SARTIME's Pharma ZLD strategy is to keep the evaporator as the final step, not the main treatment step. COD reduction and high-recovery RO reduce the reject volume first, because evaporation is the highest-energy part of ZLD.

For the reject that still reaches the final stage, SARTIME's MFTL evaporator removes the conventional calendria tube fouling bottleneck and avoids the recirculation pump seal problem. The product is positioned for higher availability and lower maintenance in final reject concentration.

RO reject minimized first evaporator feed reduced before thermal concentration Reduced choking evaporator choking reduced after upstream recovery improvement No scaling of tubes tube scaling problem removed from the operating claim High evaporator availability downtime reduced through lower fouling operation 2-20 m3/day MFTL capacity range for final ZLD reject concentration 10-20x energy burden controlled evaporation reserved for unavoidable final reject

MFTL evaporator equipment for ZLD reject concentration

MFTL evaporator mixing blade arrangement

Crystallized salt from final evaporator operation

Existing Pharma ETP / ZLD Revamp

SARTIME's revamp offering is for pharma plants that already have multiple tanks, biological treatment, RO and evaporator assets but still do not reach stable ZLD. The work starts with water audit, pollution audit, source study, treatment chemistry and operating review.

The product outcome is a corrected process, not only one more equipment addition. Depending on the finding, SARTIME may improve segregation, modify biological operation, strengthen RO pretreatment, add second-stage RO, reduce evaporator load, upgrade monitoring or intensify the existing layout to save space.

>20 pharma factories water audit and consultancy work executed for pharma industries 70% to 95% RO recovery improvement path supported by second-stage RO where required 95% space saving process intensification can replace tank-and-stirring arrangements with compact pipe-based systems Equipment-only additions avoided existing plant corrected through chemistry, source and process review Biological + RO + evaporator reviewed the full ZLD chain is checked as one operating system DBO-ready operation design, build and operate experience used to improve plant availability

Existing treatment plant revamp equipment

Finished treatment plant site after revamp

Product offerings for pharma API, formulation and injectables ZLD